Carmat (France) Today
| ALCAR Stock | EUR 1.06 0.03 2.75% |
Performance0 of 100
| Odds Of DistressLess than 41
|
Carmat is selling at 1.06 as of the 31st of January 2025; that is 2.75 percent down since the beginning of the trading day. The stock's last reported lowest price was 1.06. Carmat has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. The company was founded in 2008 and is based in Vlizy-Villacoublay, France. CARMAT operates under Medical Instruments Supplies classification in France and is traded on Paris Stock Exchange. The company has 22.67 M outstanding shares. More on Carmat
Moving together with Carmat Stock
Moving against Carmat Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Carmat Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Carmat's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Carmat or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Director | Stephane Piat |
| Business Concentration | Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) |
Carmat (ALCAR) is traded on Euronext Paris in France and employs 171 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 210.79 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Carmat's market, we take the total number of its shares issued and multiply it by Carmat's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Carmat operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 22.67 M outstanding shares.
Carmat has accumulated about 25.3 M in cash with (60.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Carmat Probability Of Bankruptcy
Ownership AllocationCarmat holds a total of 22.67 Million outstanding shares. Carmat retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Carmat Ownership Details
Carmat Risk Profiles
Although Carmat's alpha and beta are two of the key measurements used to evaluate Carmat's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.95 | |||
| Standard Deviation | 3.9 | |||
| Variance | 15.18 | |||
| Risk Adjusted Performance | (0.07) |
Carmat Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Carmat without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Carmat Corporate Directors
| Petrus Jansen | Medical Director | Profile | |
| Francesco Arecchi | Director of Marketing | Profile | |
| Eric Richez | Director of Business Development | Profile | |
| Raouia Bouyanzer | Director of Human Resources | Profile |
Additional Tools for Carmat Stock Analysis
When running Carmat's price analysis, check to measure Carmat's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmat is operating at the current time. Most of Carmat's value examination focuses on studying past and present price action to predict the probability of Carmat's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmat's price. Additionally, you may evaluate how the addition of Carmat to your portfolios can decrease your overall portfolio volatility.